Does This Deal Make Novo Nordisk Stock a Buy?

Novo Nordisk (NYSE: NVO) has faced several headwinds over the past two years. The company suffered clinical setbacks while losing market share to its biggest competitor, Eli Lilly, in the weight-loss drug space.

Another issue it had to contend with was that some online health platforms were selling compounded versions of its famous weight loss and diabetes drug, semaglutide (the active ingredient in Wegovy and Ozempic), at much lower prices, and even outside of the legally allowed exemption for doing so, that is, when there is an officially recognized shortage of the medicine.

Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »

However, Novo Nordisk recently reached an agreement with one of the leading digital health platforms that sold compounded semaglutide: Hims & Hers (NYSE: HIMS). Let’s look into the details of this deal and decide whether it makes Novo Nordisk’s shares more attractive.

Image source: Getty Images.

Shortages aside, Novo Nordisk’s GLP-1 products haven’t always been affordable for patients. That’s why many turned to platforms like Hims & Hers, which offered non-FDA (U.S. Food and Drug Administration) approved versions of these medicines at reduced prices. Of course, this meant lower sales volume and revenue for Novo Nordisk. That’s why the Denmark-based pharmaceutical leader had previously announced a patent lawsuit against Hims & Hers. However, the drugmaker has now changed its strategy.

Novo Nordisk will partner with Hims & Hers to sell the branded, FDA-approved versions of its famous drug on the telehealth platform at the same reduced self-pay prices it offers elsewhere, including on its own platform, NovoCare. This move arguably solves several problems for Novo Nordisk. Partnering with Hims & Hers, a leading distributor of compounded semaglutide, will allow the company to undercut sales of the cheap knock-offs and redirect demand toward the branded, approved version of the medicine, since the main price advantage of the former is partly gone, while the risk of taking non-FDA-approved therapies remains.

That should help boost sales volume for Novo Nordisk’s products. It will also allow the company to avoid a potentially costly and lengthy patent battle, which it may or may not have won.

Novo Nordisk has made significant headway toward solving one problem, but several remain. It is still losing ground to Eli Lilly in the weight-loss space, and the company’s revenue this year will decline, according to its own guidance. But there is good news on those fronts, too. Novo Nordisk is making progress with newer candidates. CagriSema, a next-gen GLP-1 medicine, should earn approval within 10 months.

This therapy performed better than Wegovy in clinical trials. Novo Nordisk also has several other candidates in clinical studies. Within three years or so, the company’s lineup should look different. And even though sales will drop this year, Novo Nordisk’s newer products and label expansions for Wegovy — including in treating metabolic dysfunction-associated steatohepatitis — should allow revenue growth to bounce back.

Amid all that, the stock looks dirt cheap. Novo Nordisk’s shares are trading at just 10.8x forward earnings, compared to the average of 18.5x for healthcare stocks. At current levels, Novo Nordisk is a buy.

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $511,735!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,140,464!*

Now, it’s worth noting Stock Advisor’s total average return is 946% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 12, 2026.

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Does This Deal Make Novo Nordisk Stock a Buy? was originally published by The Motley Fool

Source link

Visited 1 times, 1 visit(s) today

Related Article

Hong Kong Stock Market Midday Review

Tencent’s version of the app WorkBuddy, nicknamed ‘Little Lobster,’ has officially launched. Citi stated that there has been a significant shift in the domestic AI paradigm. According to Zhitong Finance, the Hang Seng Index rose by 1.56%, or 396 points, to close at 25,804 points, while the Hang Seng Tech Index increased by 1.4%. The

Better Artificial Intelligence (AI) Stock: Broadcom vs. AMD

Broadcom (AVGO 1.12%) and Advanced Micro Devices (AMD 2.79%) have been trailing Nvidia in the artificial intelligence (AI) chip market in recent years. Still, both companies are now experiencing a nice uptick in their growth thanks to their growing influence in this market. As it turns out, both chip designers have outperformed Nvidia stock in

UBS upgrades Rentokil to Buy with 540p target as North America turnaround takes hold

UBS upgrades Rentokil to Buy with 540p target as North America turnaround takes hold Proactive uses images sourced from Shutterstock Rentokil Initial PLC (LSE:RTO), the FTSE 100 pest control and hygiene services group, received a significant vote of confidence on Thursday as UBS upgraded the stock from neutral to buy. The Swiss bank also lifted its

Iran war threatens to upend stocks, bonds and the US dollar

New York  —  Stocks have climbed, bond yields have fallen and the US dollar has weakened across President Donald Trump’s second term so far — market movements the president has welcomed. But the war with Iran is threatening to disrupt that, sending stocks lower and pushing yields and the dollar higher. That complicates the narrative

2 Growth Stocks to Buy and Hold Forever

The best stocks to hold forever are those businesses that benefit from consistent demand, have a long runway of growth, and possess a durable competitive advantage. Once these qualities are present, you can let time and compounding do the rest of the work. Amazon (AMZN 0.78%) and The TJX Companies (TJX 1.12%) fit that profile.

High business confidence! The semiconductor sector in the Hong Kong stock market strengthens again as TianShu ZhiXin surges nearly 30%.

â‘ In the first two months, the export value of integrated circuits increased by nearly 70% year-on-year. How high is the prosperity of the industrial chain? â‘¡The semiconductor sector in Hong Kong’s stock market has once again strengthened. Which specific directions are receiving more market attention? Cailian Press reported on March 10 (Editor: Feng Yi) that

Hong Kong Stock Market Midday Review

According to Zhitong Finance, the Hang Seng Index rose by 0.08%, up 21 points, to close at 25,981 points; the Hang Seng Tech Index increased by 0.26%. The morning trading volume of Hong Kong stocks reached HKD 147.5 billion. CATL (3750.HK) surged over 8% again, with annual net profit increasing by more than 40%. Jefferies

Multiple factors drive the strength of Hong Kong stock energy storage concept; institutions predict a three-year compound annual growth rate of installations potentially reaching 50%.

â‘ Multiple factors are driving the rise of Hong Kong-listed energy storage stocks. Which individual stocks are leading in gains? â‘¡Institutions predict that installation growth could reach a compound annual growth rate (CAGR) of 50% within three years. Which sectors will emerge as new growth drivers? Cailian Press, March 11 (Editor Feng Yi) Driven by explosive

Hong Kong Stock Market Midday Review

Oil stocks continued their upward trend as the impact of strategic petroleum reserve releases weakened, and the ongoing closure of the Strait of Hormuz is expected to further push up oil prices. According to Zhitong Finance APP, the Hang Seng Index fell by 1.23%, or 319 points, to 25,579 points; the Hang Seng Tech Index

Following the doubling of the stock market, a wave of share sell-offs by major South Korean shareholders has emerged! Morgan Stanley直言states that this trend will accelerate under corporate governance reforms.

As the record-breaking rally in South Korea’s stock market continues to unfold, existing shareholders are launching a wave of share sales. JPMorgan stated that this trend is expected to further accelerate against the backdrop of South Korea’s ongoing corporate governance reforms, gradual dismantling of cross-shareholding by companies, and simplification of equity structures. As the record-breaking

2 Recession-Resistant Dividend Stocks to Buy Now

It’s always hard to predict whether a recession is coming. Even in the current environment marked by serious geopolitical tensions and lingering tariff-related volatility, some experts believe we will go through 2026 without experiencing a full-blown recession. However, it’s also always a good idea for individual investors to hold shares of companies that can perform

Stock Market Today (LIVE): Tesla’s AI Mimics Microsoft; MercadoLibre Expands In Argentina

📌 Top story — scroll down for more updates Closing Bell 4:05 pm — ORCL +9.2% today The Dow closed down nearly 300 points Wednesday as intensifying naval conflict in the Strait of Hormuz pushed West Texas Intermediate crude up 4% to $87. Markets largely shrugged off a historic 400-million-barrel reserve release from the International Energy Agency,

Jim Cramer says these 3 stock market themes could work if the oil shock eases

CNBC’s Jim Cramer is warning against trying to ignore the Iran war because rising oil prices could eventually overwhelm even the best stock ideas. “The war cannot be ring-fenced, no matter what we do. I don’t want to sugarcoat it. We can’t avoid this issue,” Cramer said on “Mad Money” on Wednesday evening. “People are

Is Archer Aviation Stock Going to $13?

Archer Aviation (NYSE: ACHR) makes an electric vertical lift aircraft called Midnight. The company is in the process of getting Midnight approved as an effective air taxi. It is an exciting concept and could create an entirely new market within the aerospace industry. But investors need to go into this stock with their eyes wide

Goldman’s Flood Sees Potential for ‘Extreme’ Rally in Stocks

Source: US Navy (Bloomberg) — Hedge fund positioning across US equities has created a setup for stocks to rip higher after their recent wobble, according to Goldman Sachs Group Inc.’s trading desk. Speculative investors have largely held on to their bullish positions in individual stocks while building hedges through bearish bets on products such as

Can Nvidia’s Stock Reach a $10 Trillion Market Cap by 2030?

Nvidia (NVDA +0.64%) is the most valuable company in the world, and there’s little wonder why that is when you see its financials. Demand for its artificial intelligence (AI) chips is through the roof, and those chips are expensive, enabling the company to grow its business at a high rate while also generating fantastic profit

2 Stocks to Buy and Hold Through Any Storm

Equity markets have been volatile this year, and market downturns have a way of testing even the most confident investors. Amid geopolitical tensions and lingering tariff-related uncertainty, some fear the stock market could take a turn for the worse by the end of the year, though no one can know for sure. But history shows

0
Would love your thoughts, please comment.x
()
x